Resources from the same session
945MO - AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)
Presenter: Ming Mo Hou
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
94MO - Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials
Presenter: Angela Lamarca
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
95MO - Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma
Presenter: Meredith Pelster
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant 945MO, 94MO and 95MO
Presenter: Lorenza Rimassa
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast
LBA78 - Overall survival of perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy: An updated analysis of RESOLVE trial
Presenter: Xiaotian Zhang
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
1512MO - Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)
Presenter: Chen Li
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA79 - GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Xiaotian Zhang
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA80 - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
Presenter: Rui-Hua Xu
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
1513MO - A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)
Presenter: Kei Muro
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA79, LBA80 and 1513MO
Presenter: Tania Fleitas
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast